Drug Profile
Equivir - GRDG Sciences
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator GRDG Sciences
- Class Antivirals; Flavonoids; Phenols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Dengue; Ebola virus infections; Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza B virus infections; Parainfluenza virus infections; Rhinovirus infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Dengue in USA
- 28 Mar 2024 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA